Ameriprise Financial Inc Mersana Therapeutics, Inc. Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 45,647 shares of MRSN stock, worth $94,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,647

Previous 45,547 0.22%

Holding current value

$94,489

Previous $91,000 5.49%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.23 - $2.25 $123 - $225	100 Added 0.22%	45,647 $86,000
Q2 2024 Aug 14, 2024	BUY	$2.0 - $4.45 $55,274 - $122,984	27,637 Added 154.31%	45,547 $91,000
Q1 2024 May 15, 2024	SELL	$2.16 - $5.94 $49,883 - $137,178	-23,094 Reduced 56.32%	17,910 $80,000
Q4 2023 Feb 14, 2024	BUY	$1.11 - $2.34 $45,514 - $95,949	41,004 New	41,004 $95,000
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $1.76 Million - $5.47 Million	572,273 New	572,273 $1.88 Million
Q4 2022 Feb 14, 2023	SELL	$5.65 - $7.86 $1,841 - $2,562	-326 Reduced 1.19%	27,044 $158,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $126,723 - $218,960	27,370 New	27,370 $185,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $129,139 - $223,696	-8,435 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $142,045 - $232,721	8,435 New	8,435 $225,000
Q4 2019 Feb 14, 2020	SELL	$1.45 - $6.73 $28,253 - $131,134	-19,485 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.54 - $4.2 $31,386 - $85,600	-20,381 Reduced 51.12%	19,485 $31,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $153,085 - $255,142	39,866 New	39,866 $161,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $201M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Mersana Therapeutics, Inc. Transaction History